Delving into the Latest Updates on Interferon alfa-2a, recombinant with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

Interferon alfa-2a, Interferon alpha-2a, RIFN-ALPHA2A

+ [8]

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators, Innate antiviral immune response inducers

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [4]

Active Indication-

Inactive Indication

Follicular LymphomaHairy Cell LeukemiaHepatitis C+ [3]

Originator Organization

F. Hoffmann-La Roche Ltd.

Active Organization-

Inactive Organization

Hoffmann-La Roche, Inc.

Active Biotech AB

TaiGen Biotechnology Co., Ltd.

Drug Highest PhaseWithdrawn

First Approval Date

US (03 Jun 1986),

Hairy Cell LeukemiaHepatitis CPhiladelphia chromosome positive chronic myelogenous leukemia

RegulationOrphan Drug (US)

Login to view timeline

Gene Sequence

Sequence Code 32821

Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with refractory Behçet's uveitis (BDU). Half of the participants will receive IFNα2a while the other half will receive CsA.

Start Date30 Jun 2017

Sponsor / Collaborator

Peking Union Medical College Hospital

EUCTR2014-005390-36-GB / Unknown statusPhase 3IIT

Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’S

Start Date17 Feb 2016

Sponsor / Collaborator

The University of Liverpool

NCT02340962 / CompletedPhase 2

Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination with Peg-interferon and Ribavirin in Treatment Naïve East Asian Subjects with Chronic Hepatitis C Virus Genotype 1b Infection.

Start Date01 May 2015

Sponsor / Collaborator

TaiGen Biotechnology Co., Ltd.

100 Clinical Results associated with Interferon alfa-2a, recombinant

Login to view more data

100 Translational Medicine associated with Interferon alfa-2a, recombinant

Login to view more data

100 Patents (Medical) associated with Interferon alfa-2a, recombinant

Login to view more data

1,055

Literatures (Medical) associated with Interferon alfa-2a, recombinant

31 Dec 2024·Journal of Dermatological Treatment

Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients

Article

Author: Yang, Lu ; Song, Hongbin ; Lu, Lu ; Wang, Tao ; Feng, Jindi ; Zhang, Shiyu ; Hu, Zhonghui ; Liu, Yuehua

Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma.Objectives: This study was conducted to evaluate efficacy and safety of interferon (IFN) α-2a combined with phototherapy for early-stage MF.Methods: Thirteen patients with early-stage MF received subcutaneous injections of IFN α-2a at 3 million IU combined with phototherapy three times per week for 6 months. Treatment efficacy was measured by changes in body surface area (BSA) score and modified severity-weighted assessment tool (mSWAT) score at 1, 3, and 6 months after treatment. Histopathologic examinations of skin lesions were performed before and after treatment.Results: After 3 months of treatment, all 13 patients achieved a partial response, and BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001). After 6 months, BSA and mSWAT scores were significantly lower than those at baseline (p < 0.001) and after 3 months (p < 0.05). Eleven patients achieved complete remission and two patients achieved a partial response (overall response rate, 100%). Histopathologic examination showed a significant decrease in the number of atypical lymphocytes in both epidermis and dermis. No severe adverse effects occurred.Conclusion: IFN α-2a in combination with phototherapy may be an effective and safe alternative modality for early-stage MF.

01 Jul 2024·Journal of Hepatology

PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial

Article

Author: Zhu, Haoxiang ; Zhang, Qiran ; Liu, Yanhong ; Chen, Liang ; Zhang, Xinxin ; Li, Fahong ; Yu, Jie ; Qi, Xun ; Guo, Yifei ; Zhang, Jiming ; Huang, Yuxian ; Shen, Zhongliang ; Zhang, Wenhong ; Wu, Xiaoping ; Qu, Lihong ; Wang, Jinyu ; Zhang, Fengdi ; Yang, Feifei ; Mao, Richeng ; Zhang, Yongmei ; Li, Qingxing

BACKGROUND & AIMSNucleo(s)tide analogue (NUC) cessation can lead to hepatitis B surface antigen (HBsAg) clearance but also a high rate of virological relapse. However, the effect of pegylated interferon alpha-2a (PegIFN-α-2a) on virological relapse after NUC cessation is unknown. Therefore, this study aimed to evaluate the effect of switching from NUC to PegIFN-α-2a treatment for 48 weeks on virological relapse up to week 96.METHODSIn this multicenter randomized-controlled clinical trial, 180 non-cirrhotic patients with HBeAg-negative chronic hepatitis B on continuous NUC therapy for ≥2.5 years, with HBV DNA levels <60 IU/ml, were randomized to discontinue NUC therapy (n = 90) or receive 48 weeks of PegIFN-α-2a treatment (n = 90). Patients were followed up for up to 96 weeks. The primary endpoint was the virological relapse rate up to week 96.RESULTSIntention-to-treat analysis revealed patients in the interferon monotherapy group had significantly lower cumulative virological relapse rates than the NUC cessation group until week 96 (20.8% vs. 53.6%, p <0.0001). Consistently, a significantly lower proportion of patients in the interferon monotherapy group had virological relapse than those in the NUC cessation group at 48 weeks off treatment (17.8% vs. 36.7%, p = 0.007). The virological relapse rate positively correlated with HBsAg levels in the NUC cessation group. The interferon monotherapy group had a lower cumulative clinical relapse rate (7.8% vs. 20.9%, p = 0.008) and a higher HBsAg loss rate (21.5% vs. 9.0%, p = 0.03) than the NUC cessation group.CONCLUSIONSSwitching from NUC to PegIFN-α-2a treatment for 48 weeks significantly reduces virological relapse rates and leads to higher HBsAg loss rates than NUC treatment cessation alone in patients with HBeAg-negative chronic hepatitis B.IMPACT AND IMPLICATIONSNucleo(s)tide analogue (NUC) cessation can lead to HBsAg clearance but also a high rate of virological relapse, but an optimized scheme to reduce the virological relapse rate after NUC withdrawal is yet to be reported. This randomized-controlled trial investigated the effect of switching from NUC to PegIFN-α-2a treatment for 48 weeks on virological relapse up to week 96 in patients with HBeAg-negative chronic hepatitis B. The interferon monotherapy group had a significantly lower cumulative virological relapse rate (20.8% vs. 53.6%, p <0.0001) and higher HBsAg loss rate (21.5% vs. 9.0%, p = 0.03) than the NUC cessation group up to week 96. This provides an optimized strategy for NUC cessation in HBeAg-negative patients.TRIAL REGISTRATION NUMBERNCT02594293.

02 Jan 2024·Ocular Immunology and Inflammation

Cerebro-Ocular Toxocariasis Revealed by Bilateral Cystoid Macular Edema

Article

Author: Tadayoni, Ramin ; Paris, Arianna ; Hié, Miguel ; Bodaghi, Bahram ; Touhami, Sara

DESIGNCase Report Case description: This report describes the case of a female patient diagnosed with oculo-cerebral toxocariasis manifesting initially in the form of isolated bilateral cystoid macular edema. Diagnosis was made by means of positive anterior chamber and lumbar puncture western blots. The unusual presentation, ancillary findings and treatment are discussed. The control of intraocular inflammation that was only partially responsive to steroids was eventually achieved with pegylated interferon alfa-2a.CONCLUSIONIsolated macular edema is a rare presentation of ocular toxocariasis. Interferon alfa-2a may prove useful in case of insufficient control of inflammation.

100 Deals associated with Interferon alfa-2a, recombinant

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB04	DB00034

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Cell Carcinoma	Preclinical	RU	Active Biotech AB	01 Jan 2007
Renal Cell Carcinoma	Preclinical	RO	Active Biotech AB	01 Jan 2007
Renal Cell Carcinoma	Preclinical	BG	Active Biotech AB	01 Jan 2007
Renal Cell Carcinoma	Preclinical	UA	Active Biotech AB	01 Jan 2007
Follicular Lymphoma	Preclinical	SE	Hoffmann-La Roche, Inc.	01 Oct 2002
Follicular Lymphoma	Preclinical	NO	Hoffmann-La Roche, Inc.	01 Oct 2002
Follicular Lymphoma	Preclinical	DK	Hoffmann-La Roche, Inc.	01 Oct 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PO283 (AAO2018)	Not Applicable	Behcet's uveitis	-	Interferon alfa-2a	agjnebyfei(ypksdsiwor) = jarxvbzkaj ygaomxvegl (yywzhazwcw ) View more	Positive	28 Oct 2018
				Interferon Alfa-2A	agjnebyfei(ypksdsiwor) = iuzwveyiez ygaomxvegl (yywzhazwcw ) View more
NCT02340962 (CTgov)	Phase 2	Chronic hepatitis C genotype 1b	25	Interferon Alfa-2a+TG-2349+Ribavirin (Group I)	hxqwzwrwkn(tlmwjshjwm) = kxjkoibvpj jzjxzwjnxo (kfuwvopirw, kdutzbaqiv - xdghpltixt) View more	-	12 Oct 2018
				Interferon Alfa-2a+TG-2349+Ribavirin (Group II)	hxqwzwrwkn(tlmwjshjwm) = rodsxyecbf jzjxzwjnxo (kfuwvopirw, ngmmiflrdb - yqncodjgxi) View more
ARVO2017	Not Applicable	Behcet Syndrome	-	Interferon alpha-2a	(qkwmocldtz) = behvpvmfrd kenrbcfran (wvqtbcrvtb, (11 - 30)) View more	-	07 May 2017
				Anti TNF-alpha	(qkwmocldtz) = duxmeiipdp kenrbcfran (wvqtbcrvtb, (6 - 20)) View more
NCT00738530 (AVOREN, CTgov)	Phase 3	Metastatic Renal Cell Carcinoma \| Metastatic Clear Cell Renal Cell Carcinoma	649	Interferon alfa 2a [Roferon]+Bevacizumab [Avastin] (Bevacizumab + IFN-Alfa-2A)	awcuicxegw(zkgehlzrya) = klhzsdlirz aeijiedbvd (adjyamkfkf, sbyszfhhqs - xbxxzogutr) View more	-	23 Jun 2016
				Placebo+Interferon alfa 2a [Roferon] (Placebo + IFN-Alfa-2A)	awcuicxegw(zkgehlzrya) = ossfvavovw aeijiedbvd (adjyamkfkf, jksbjfxejx - mjqvubqxtk) View more
ASCO2015	Not Applicable	Polycythemia Vera \| Thrombocythemia, Essential	42	IFN-ALPHA2a (Polycythemia vera)	elsiuuatlz(utexlyxmez) = pqkywdhsvb rkpwqiyvds (curgdtjqup )	-	20 May 2015
				IFN-ALPHA2a (Essential thrombocytemia)	elsiuuatlz(utexlyxmez) = wvtaphsfew rkpwqiyvds (curgdtjqup )
NCT00333840 (CTgov)	Phase 3	Philadelphia chromosome positive chronic myelogenous leukemia	1,106	interferon-alpha (INF-a)+imatinib mesilate+cytarabine (ARA-C)	avkltatshw(hzhmggntsv) = gnxizjwwpm aamfpjfuit (zfgfjtlxje, etvuklcarh - yjuassabdn) View more	-	14 Oct 2013
NCT00796757 (BEVLiN, Pubmed \| Ann Oncol) Manual	Phase 2	Metastatic Renal Cell Carcinoma First line	146	bevacizumab+Interferon alfa-2a	(iioditmdnv) = uuqiscagql xsawvrhmvj (bzrojhvisg, 11.7 - 18.0) View more	Positive	01 Sep 2013
Ege University Department of Ophtalmology (EULAR2013)	Not Applicable	Behcet's uveitis	23	Interferon alpha 2a	qozrfbrado(cmouncvxmh) = flu-like symptoms were observed in the vast majority of the patients without necessitating interruption of the treatment sehqlgthur (xzgqwhewni ) View more	Positive	12 Jun 2013
ARVO2013	Not Applicable	Macular Edema	7	Interferon alpha-2a	(gtqksdbvjz) = Only 1 patient discontinued treatment after 21 months due to side effects (persistent fatigue; CME in remission) dwyemqypls (btdjmotmsd ) View more	-	01 Jun 2013
NCT00738530 (AVOREN, Pubmed \| Lancet) Manual	Phase 3	Metastatic Renal Cell Carcinoma First line	649	bevacizumab+interferon alfa-2a	(kyppuykbda) = yxubcdzqqy uxjzoznxvx (qevjjeahit ) View more	Positive	22 Dec 2007
				Placebo+interferon alfa-2a	(kyppuykbda) = alfiwpwtpv uxjzoznxvx (qevjjeahit ) View more